CSI Market
Sign In | Register

Cogent Biosciences Inc (COGT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access COGT Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Cogent Biosciences Inc adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-193.76
Depreciation & amortization1.37
Amortization of Other Assets0.56
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets to be Disposed of0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.13
Share-based Compensation34.02
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Premiums Paid On Marketable Securities-
Marketable Securities Realized Gain Loss-
Increase Decrease In Operating Lease Right Of Use Asset-
Increase Decrease In Operating Leases-0.42
Operating Lease Right Of Use Asset Amortization Expense0.53
Debt Discount Included In Accrued Expenses And Other Liabilities-
Debt Issuance Costs Included In Accounts Payable And Accrued Expenses-
Offering Costs Included In Accounts Payable And Accrued Expenses-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-2.02
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities-2.58
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets1.54
Other Working Capital-1.31
Other Noncash Income (Expense)0.00
Other net2.14
Payments for (Proceeds from) Other Operating Activities-3.98
Discontinued operations0.00
Net Cash flow from Operating Activities-164.15
Investing Activities
Capital Expenditures-0.82
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities195.29
Payments to Acquire Marketable Securities-216.65
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-22.18
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock9.77
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net45.72
Proceeds From Issuance Underwritten Public Offering-
Payment To Contingent Value Right Holders-
Payments To Contingent Value Right Holders-
Proceeds From Issuance Of Common Stock And Preferred Stock Net Of Offering Costs-
Proceeds From Issuance Under At The Market Offering45.71
Proceeds From Convertible Senior Notes-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities55.49
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-164.97
Total Cash Flow-130.84
4 historic quarters locked

Sign in to unlock the full Cogent Biosciences Inc cash flow history.

Sign In Create Free Account

About Cogent Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-342393

Figures are derived from filed reports and may be restated. Historical data is subject to revision.